Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sargramostim
- Development stage
- Approved
- Lead developer
- Partner Therapeutics
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous, Inhalation
01
Overview
Sargramostim is a recombinant, yeast-derived form of human granulocyte-macrophage colony-stimulating factor (GM-CSF), a glycoprotein that stimulates the proliferation, differentiation, and activation of hematopoietic progenitor cells. It is used to accelerate recovery of neutrophils and other myeloid cells after chemotherapy or bone marrow transplantation, to mobilize peripheral blood progenitor cells for collection by leukapheresis, and to reduce the risk of infection in patients with acute myelogenous leukemia (AML) receiving chemotherapy. Sargramostim also improves survival following exposure to myelosuppressive doses of radiation. Its mechanism involves binding to the GM-CSF receptor on hematopoietic cells, activating JAK2/STAT1/STAT3 signaling pathways that promote cell survival and proliferation[1][4][9].
- Brand names
- LeukineLeukine LiquidProkineSargmalin
- Other names
- recombinant human granulocyte-macrophage colony stimulating factorrecombinant human GM-CSFrhuGM-CSF
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on sargramostim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sargramostim.